Michel Steinmetz

Title: Michel Steinmetz: Advancing Parasite-Targeted Drug Research

Introduction

Michel Steinmetz is an inventor based in Basel, Switzerland, associated with the Paul Scherrer Institut. His patent work explores a potential way to inhibit protozoan replication by targeting parasite tubulin while sparing mammalian host cells. His listed portfolio includes 1 patent.

Latest Patents

Steinmetz’s patent, “Use of parabulin for targeting protozoan tubulin for the inhibition of protozoan replication,” describes using parabulin or its derivatives to target protozoan tubulin. The invention builds on the finding that apicomplexan tubulin is essential to parasites and may offer a drug target distinct from mammalian tubulin.

The patent describes parabulin as a compound that destabilizes parasite microtubules and inhibits processes involved in parasite replication and host-cell invasion. By selectively targeting parasite structures, the approach aims to limit harm to the mammalian host and offers a potential strategy for addressing the development of drug resistance.

The patent identifies parabulin’s molecular weight as 373.4 Da and gives its chemical name as 3-(3,4-dimethoxyphenyl)-N-[(3,4,5-trimethoxyphenyl)methyl]prop-2-enamide. The disclosed work presents this compound as a candidate for further investigation in protozoan disease research.

Career Highlights

Steinmetz’s listed patent connects his work with research at the Paul Scherrer Institut, where the invention addresses parasite biology and potential therapeutic targeting. Its focus is the selective disruption of protozoan microtubules, which are important to parasite replication and invasion of host cells.

Collaborations

The supplied information names Natacha Gaillard and Ashwani Sharma as Steinmetz’s coworkers. Their specific roles in the patent or related research are not detailed in the available information.

Conclusion

Michel Steinmetz’s patent presents parabulin-based targeting of protozoan tubulin as a potential approach to inhibiting parasite replication while sparing mammalian cells.